U.S. FOOD & DRUG ADMINISTRATION
OFFICE OF REGULATORY AFFAIRS
OFFICE OF PHARMACEUTICAL QUALITY OPERATIONS

May 3, 2023

VIA Electronic Mail
Return Confirmation Requested

Matt McDonald, Owner
Triad Rx, Inc.
26258 Pollard Rd.
Daphne, AL 36526-4250

Dear Mr. McDonald:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm's corrective actions in response to our warning letter [WL 569659 Issued February 5, 2019]. We acknowledge that your firm no longer produces sterile drug products. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA's implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,

Ronda R. Loyd-jones -S
Digitally signed by Ronda R. Loyd-jones -S
Date: 2023.05.03 12:18:50 -07'00'

Ronda R. Loyd-Jones
Director, Compliance Branch
Office of Pharmaceutical Quality Operations, Division II

U.S. Food and Drug Administration
Office of Pharmaceutical Quality Operations, Division II
1201 Main Street, Suite 7200
Dallas, Texas 75202
www.fda.gov